Management plans to provide revised financial expectations with third-quarter earnings in late October.
Boston Scientific said Tuesday it is unlikely to meet the full-year 2026 financial guidance it issued earlier this year, citing the ongoing impact of a cyberattack the company first disclosed on . The company hasn't yet provided specific revised figures, saying a formal update will come alongside its third-quarter earnings call, scheduled for .
Reuters, CNBC and MedTech Dive reported the warning and earlier incident. The precise scope of the disruption remains unclear, including whether it affected manufacturing, order processing, shipping or several operations. Management has yet to quantify the expected effect on its financial targets.
Financial impact remains unclear
Investors may have to wait until late October for a fuller estimate. The early warning establishes that the incident threatens the existing outlook, but it does not yet provide a basis for estimating the size of the shortfall.
The next scheduled update is , when Boston Scientific plans to discuss revised guidance alongside its quarterly results.